Spectral AI (NASDAQ:MDAI – Get Free Report) is one of 228 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it compare to its rivals? We will compare Spectral AI to similar companies based on the strength of its earnings, institutional ownership, risk, dividends, profitability, analyst recommendations and valuation.
Profitability
This table compares Spectral AI and its rivals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Spectral AI | -89.85% | N/A | -104.64% |
Spectral AI Competitors | -563.96% | -136.63% | -25.35% |
Insider & Institutional Ownership
67.1% of Spectral AI shares are owned by institutional investors. Comparatively, 48.0% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 56.7% of Spectral AI shares are owned by insiders. Comparatively, 15.4% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Analyst Recommendations
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Spectral AI | 0 | 0 | 3 | 1 | 3.25 |
Spectral AI Competitors | 1796 | 4748 | 8810 | 258 | 2.48 |
Spectral AI currently has a consensus price target of $4.50, suggesting a potential upside of 235.82%. As a group, “Surgical & medical instruments” companies have a potential upside of 20.02%. Given Spectral AI’s stronger consensus rating and higher possible upside, equities analysts clearly believe Spectral AI is more favorable than its rivals.
Valuation & Earnings
This table compares Spectral AI and its rivals top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Spectral AI | $22.53 million | -$20.85 million | -1.00 |
Spectral AI Competitors | $1.06 billion | $4.65 million | 5.26 |
Spectral AI’s rivals have higher revenue and earnings than Spectral AI. Spectral AI is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Spectral AI has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Spectral AI’s rivals have a beta of 0.54, suggesting that their average stock price is 46% less volatile than the S&P 500.
Summary
Spectral AI beats its rivals on 9 of the 13 factors compared.
Spectral AI Company Profile
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.
Receive News & Ratings for Spectral AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral AI and related companies with MarketBeat.com's FREE daily email newsletter.